Table 1. Main characteristics and results of the eligible studies.
No. of paper | First author | Journal | Year | Country | Methods | Duration of Follow-up (months) | Cut-off point (high/low) | No.of patients | No.of Deceased/Alive |
(1) | L. M. Sholl | Am J Surg Pathol | 2010 | USA | IHC | 136 | >5% (52/52) | 104 | 57/47 |
(2) | P. Yuan | PLoS One | 2010 | USA | IHC | - | SCC (high >270, low <140) (29/11); ADC (high>193, low <10) (9/8) | 57 | - |
(3) | Y. Lu | PLoS One | 2010 | USA | IHC | 48 | >5% (19/89) | 89 | 33/13* |
(4) | T. Wilbertz1 | Mod Pathol | 2011 | Switzerland/USA | FISH | 169 | >30% (225/533) | 758 | 235/33* |
(5) | Y. R. Cai | Oncol Lett | 2011 | China | qPCR | - | Ratio>M +2 SD (30/85) | 115 | - |
(6) | X. X. Li | Int J Mol Sci | 2012 | China | IHC | 12 | ≥10% (31/13) | 44 | 31/13 |
(7) | H. Sasaki | Exp Ther Med | 2012 | Japan | qPCR | 120 | Ratio>4 copies(42/85) | 127 | 91/36 |
(8) | V. Velcheti | PLoS One | 2013 | Greece/USA | IF | 60 | Score>193(418/229) | 647 | 392/255 |
Abbreviations: IHC, immunohistochemistry; qPCR, quantitative real-time polymerase chain reaction; FISH, fluorescence in situ hybridization; IF, immunofluorescence; SCC, squamous cell carcinomas; ADC, adenocarcinomas; M, mean; SD, standard deviation.
Note:
only with SCC patients;